Inflammatory diseases

Laboratory research
#Autoimmune disease #Inflammatory diseases #Nimbus #Phase I trial

First-in-class SIK2 inhibitor enters Phase I trial

Nimbus Therapeutics has dosed the first subjects in its Phase I clinical trial of NDI-225673, a highly selective inhibitor of salt-inducible kinase 2 (SIK2) for the potential treatment of immune-mediated inflammatory diseases.   The Phase I trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and… Read More

#News

#Autoimmune disease #Collaboration #Evotec #Inflammatory diseases #Odyssey Therapeutics

Evotec joins Odyssey in autoimmune drug development

Evotec has entered a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments in autoimmune and inflammatory diseases.  Under the agreement, Odyssey will use Evotec's data-driven discovery platform, screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease… Read More

#Business & Investment #News

Fibrous dysplasia disease
#Fibrotic disease #Inflammatory diseases #Macrophages #Resolution Therapeutics

Resolution extends pipeline with in vivo RMT 

Resolution Therapeutics has extended its inflammatory and fibrotic disease pipeline with its in vivo regenerative macrophage therapy (RMT).  The announcement comes with Resolution executing Material Transfer Agreements with independent, best-in-class lipid nanoparticle (LNP) technology providers. Under the agreements, Resolution will conduct systematic assessments of LNP formulations for the engineering… Read More

#News

#Bacteria #Gut microbiome #Infectious diseases #Inflammatory diseases

Engineered gut bacteria could be viable alternative to FMT

An engineered gut bacteria therapy could be an alternative to foecal microbiota transplants (FMT), researchers say.  Results from a Phase Ib clinical study demonstrate comparable safety and efficacy between stool-based FMT and manufactured live biotherapeutic product (LBP).  Scientists at the Icahn School of Medicine at Mount Sinai, New York developed the… Read More

#News

Medical research
#Evotec #Inflammatory diseases #Preclinical development

Evotec nominates PDC for inflammatory skin disease programme 

Evotec has nominated its small molecule preclinical development candidate (PDC) as it advances a programme for inflammatory skin diseases.  The programme, developed as part of an alliance in medical dermatology with Almirall announced in 2022, will develop novel treatments for immune-mediated inflammatory skin diseases with high unmet… Read More

#News

#Autoimmune disease #Biotechnology #Inflammatory diseases

Laigo Bio announces new CSO as part of board appointments 

Biotechnology company Laigo Bio has appointed Dr Richard Sainson as Chief Scientific Officer as part of a swathe of board appointments.  The company, which specialises in autoimmune and inflammatory diseases, says Sainson will lead scientific strategy and oversee the advancement of Laigo’s proprietary SureTACs platform and programmes towards the clinic.   Sainson has over 25… Read More

#News